Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumothorax | 2 | 2019 | 82 | 0.680 |
Why?
|
| Electric Impedance | 2 | 2019 | 70 | 0.590 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 3 | 2019 | 41 | 0.330 |
Why?
|
| Pleura | 2 | 2019 | 27 | 0.300 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2019 | 79 | 0.290 |
Why?
|
| Abortion, Induced | 1 | 2024 | 85 | 0.200 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2022 | 77 | 0.180 |
Why?
|
| Benzamides | 2 | 2019 | 120 | 0.180 |
Why?
|
| Obstetrics | 1 | 2024 | 245 | 0.170 |
Why?
|
| Hysterectomy | 1 | 2022 | 203 | 0.170 |
Why?
|
| Pyridines | 2 | 2019 | 251 | 0.170 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 314 | 0.170 |
Why?
|
| Placenta Accreta | 1 | 2022 | 163 | 0.160 |
Why?
|
| Transducers | 1 | 2019 | 22 | 0.160 |
Why?
|
| Cesarean Section | 1 | 2022 | 422 | 0.150 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2019 | 146 | 0.150 |
Why?
|
| Mental Health | 1 | 2022 | 363 | 0.150 |
Why?
|
| Paired Box Transcription Factors | 1 | 2018 | 75 | 0.150 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2019 | 52 | 0.140 |
Why?
|
| Tidal Volume | 1 | 2018 | 41 | 0.140 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 694 | 0.140 |
Why?
|
| Histone Deacetylases | 1 | 2018 | 113 | 0.140 |
Why?
|
| Fluoroscopy | 1 | 2018 | 92 | 0.140 |
Why?
|
| Computational Biology | 2 | 2019 | 834 | 0.130 |
Why?
|
| DNA Helicases | 1 | 2018 | 229 | 0.130 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2018 | 219 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2019 | 466 | 0.130 |
Why?
|
| Receptors, Somatomedin | 1 | 2016 | 21 | 0.130 |
Why?
|
| Influenza, Human | 1 | 2022 | 674 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2019 | 345 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 1137 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 1126 | 0.120 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 489 | 0.110 |
Why?
|
| Meningeal Neoplasms | 1 | 2016 | 175 | 0.110 |
Why?
|
| Depression | 1 | 2022 | 1293 | 0.100 |
Why?
|
| Cerebellar Neoplasms | 1 | 2016 | 314 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 1204 | 0.100 |
Why?
|
| Medulloblastoma | 1 | 2016 | 378 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2018 | 872 | 0.090 |
Why?
|
| Cell Line, Tumor | 4 | 2019 | 3498 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2018 | 2337 | 0.080 |
Why?
|
| Mice, Inbred NOD | 2 | 2019 | 289 | 0.070 |
Why?
|
| Vincristine | 2 | 2019 | 190 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2019 | 105 | 0.070 |
Why?
|
| Animals | 5 | 2019 | 33051 | 0.070 |
Why?
|
| Pregnancy | 3 | 2024 | 7373 | 0.060 |
Why?
|
| 1,2-Dimethylhydrazine | 1 | 2022 | 6 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2022 | 3314 | 0.050 |
Why?
|
| Gynecology | 1 | 2024 | 128 | 0.050 |
Why?
|
| Placenta Previa | 1 | 2022 | 66 | 0.050 |
Why?
|
| Female | 7 | 2024 | 68330 | 0.050 |
Why?
|
| Child Health | 1 | 2022 | 64 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2022 | 148 | 0.040 |
Why?
|
| Chest Tubes | 1 | 2019 | 37 | 0.040 |
Why?
|
| Suction | 1 | 2019 | 50 | 0.040 |
Why?
|
| Histone Deacetylase 1 | 1 | 2019 | 20 | 0.040 |
Why?
|
| Sus scrofa | 1 | 2019 | 115 | 0.040 |
Why?
|
| Humans | 8 | 2024 | 126753 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 4429 | 0.040 |
Why?
|
| PAX3 Transcription Factor | 1 | 2018 | 29 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2019 | 232 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2019 | 101 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 190 | 0.040 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2018 | 100 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2019 | 229 | 0.040 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2018 | 72 | 0.040 |
Why?
|
| Dogs | 1 | 2019 | 604 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2018 | 222 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 361 | 0.030 |
Why?
|
| Mice | 3 | 2019 | 17596 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2019 | 568 | 0.030 |
Why?
|
| Cellular Reprogramming | 1 | 2019 | 105 | 0.030 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 1758 | 0.030 |
Why?
|
| Equipment Design | 1 | 2019 | 575 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2022 | 826 | 0.030 |
Why?
|
| Vaccination | 1 | 2022 | 1004 | 0.030 |
Why?
|
| Adolescent | 3 | 2022 | 20002 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2019 | 277 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 1048 | 0.030 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2016 | 39 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2016 | 42 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 85 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 946 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2016 | 50 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2016 | 92 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2016 | 125 | 0.030 |
Why?
|
| Anxiety | 1 | 2022 | 964 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 416 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2016 | 299 | 0.030 |
Why?
|
| Child | 3 | 2022 | 25101 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 628 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2016 | 316 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 774 | 0.030 |
Why?
|
| Texas | 1 | 2022 | 3551 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 2225 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 3907 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2024 | 1195 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 380 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 708 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 849 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2019 | 1842 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1302 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2022 | 6214 | 0.020 |
Why?
|
| Gene Expression | 1 | 2016 | 1482 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1753 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1931 | 0.020 |
Why?
|
| Male | 3 | 2024 | 62543 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2022 | 8347 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 6134 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 2397 | 0.020 |
Why?
|
| United States | 1 | 2024 | 11310 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 1560 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2019 | 14347 | 0.010 |
Why?
|
| Adult | 1 | 2024 | 30410 | 0.010 |
Why?
|